- Learn the basics
- Find stocks
- Understand a stock
- Compare with peers
Can-Fite BioPharma Ltd.
CANF Israel NYSECan-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.
In short
Loading the key numbers…
What the sector means for this company
These sentences describe the numbers; they are not a recommendation. This content is not investment advice.
Price chart: each candle shows one day's opening, highest, lowest and closing price. The projection line is our model's estimate - a model, not a promise.
Price chart
The bars show each projection's high and low scenario. The more likely an outcome, the more solid its half of the bar: for the DCF, how often 400 simulations of the company's growth and margins reach that scenario; for the growth plans, up means the plans succeed and no expected decline hits, down means the plans fail and the declines hit. Switch them off with Ranges.
Key statistics: the most used ratios in one place. Tap the icon next to a name for a short explanation. Compare them with similar companies, not with the whole market.
Financial statements: the income statement shows sales and profit, the balance sheet what the company owns and owes, and the cash flow statement the money that actually came in and went out. How to read them.
Company policy and leadership: an AI-assisted assessment of how the company sells, executes, uses its resources and treats people, production and service. Read it as a starting point for your own research.
News: the latest articles about the company, grouped by day. Each has ratings for the outlet's stance towards the company, how factual it is and the market mood it conveys (an animal label such as Bull or Bear - hover it for the meaning). What the ratings mean.
More Health Care stocks
- BullFrog AI Holdings, Inc. (BFRG)
- BullFrog AI Holdings, Inc. (BFRGW)
- Burning Rock Biotech Ltd (BNR)
- Butterfly Network, Inc. (BFLY)
- C4 Therapeutics, Inc. (CCCC)
- Cabaletta Bio, Inc. (CABA)
- Cadre Holdings, Inc. (CDRE)
- Cadrenal Therapeutics, Inc. (CVKD)
- CalciMedica, Inc. (CALC)
- Calidi Biotherapeutics, Inc. (CLDI)
- Camp4 Therapeutics Corp (CAMP)
- Camtek Ltd (CAMT)
- Candel Therapeutics, Inc. (CADL)
- Canopy Growth Corp (CGC)
- Capricor Therapeutics, Inc. (CAPR)
- CapsoVision, Inc (CV)
- Cardiff Oncology, Inc. (CRDF)
- Cardio Diagnostics Holdings, Inc. (CDIO)
- Cardio Diagnostics Holdings, Inc. (CDIOW)
- CareDx, Inc. (CDNA)
- Caribou Biosciences, Inc. (CRBU)
- Caris Life Sciences, Inc. (CAI)
- Carlsmed, Inc. (CARL)
- Cartesian Therapeutics, Inc. (RNAC)